<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95650">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01749956</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI GI 168</org_study_id>
    <nct_id>NCT01749956</nct_id>
  </id_info>
  <brief_title>5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer</brief_title>
  <official_title>A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients With Stage II/III Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase II study will be to investigate the antiangiogenic agent,
      aflibercept, in combination with chemoradiation as preoperative treatment for patients with
      stage II/III rectal cancer, followed by 4 months of FOLFOX6 plus aflibercept adjuvantly.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>15 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the toxicity of this regimen</measure>
    <time_frame>15 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate incidence of local and distant recurrence, overall survival (OS) and disease-free survival (DFS)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the sphincter preservation rate</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the levels of vascular endothelial growth factor A (VEGF-A) and placental growth factor (PLGF) and correlate with response</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX6/Aflibercept/Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative Chemoradiation:
5-FU: 225 mg/m2 per day by intravenous continuous infusion (IVCI), Days 1 thru 42;
Radiation: 50.4 Gy (1.8 Gy/day or 28 fractions) Mon thru Fri, Weeks 1 thru 6;
Aflibercept: 4 mg/ kg, via IV infusion, Days 1 and 15.
Surgery:  Patients will undergo abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines.
Postoperative Chemotherapy and Aflibercept Treatments:
Aflibercept (administered first): 4 mg/kg IV for approximately 1 hour (no more than 2 hours) on Days 1 and 15 of each cycle.
Modified FOLFOX6:
Leucovorin: 400 mg/m2 as a 2-hour infusion prior to 5-FU on Days 1 and 15 of  each cycle.
Oxaliplatin: 85 mg/m2 IV as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.
5-FU: 400-mg/m2 bolus for 2 to 4 minutes followed by 2400 mg/m2 for 46 hours on Days 1 and 15 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <arm_group_label>FOLFOX6/Aflibercept/Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <arm_group_label>FOLFOX6/Aflibercept/Radiation Therapy</arm_group_label>
    <other_name>Eylea</other_name>
    <other_name>Zaltrap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines</description>
    <arm_group_label>FOLFOX6/Aflibercept/Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX6</intervention_name>
    <arm_group_label>FOLFOX6/Aflibercept/Radiation Therapy</arm_group_label>
    <other_name>Leucovorin (Folinic Acid)</other_name>
    <other_name>5-Fluorouracil (5-FU; Efudex)</other_name>
    <other_name>Oxaliplatin (Eloxatin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed stage II or III rectal cancer (adenocarcinoma)

          2. Patients must be candidates for preoperative chemoradiation

          3. Male or female patients ≥18 years-of-age

          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or (see
             Appendix A)

          5. Adequate hematologic function (within 7 days prior to initial treatment) defined as:

             Absolute neutrophil count (ANC) ≥1500/μL Platelets ≥100,000/uL Hemoglobin ≥9 g/dL

          6. Adequate liver function defined as:

             Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline
             phosphatase (ALP) ≤3 x the upper limit of normal (UNL) Total bilirubin ≤3.0 mg/dL

          7. Adequate renal function defined as serum creatinine ≤1.6 mg/dL

          8. Male patients willing to use adequate contraceptive measures (see Appendix B)

          9. Female patients who are not of child-bearing potential (see Appendix B), and female
             patients of child-bearing potential who agree to use adequate contraceptive measures
             (see Appendix B), who are not breastfeeding, and who have a negative serum or urine
             pregnancy test &lt;7 days prior

         10. Life expectancy ≥12 weeks

         11. Willingness and ability to comply with the trial and follow-up procedures

         12. Ability to understand the nature of this trial and give written informed consent.

        Exclusion Criteria:

          1. Treatment with prior chemotherapy or radiation for rectal cancer.

          2. Patients who have received any other investigational agents within the 28 days prior
             to Day 1 of the study.

          3. Known to be human immunodeficiency virus positive or hepatitis B or C positive

          4. Women who are pregnant or breastfeeding

          5. History of acute myocardial infarction within the previous 6 months, uncontrolled
             hypertension (blood pressure &gt;150/100 mmHg and/or diastolic blood pressure &gt;100
             mmHg), unstable angina, New York Heart Association Grade 2 or greater congestive
             heart failure (see Appendix C), serious cardiac arrhythmia requiring medication
             (excluding atrial fibrillation), or ≥ Grade 2 peripheral vascular disease.

          6. History of hypertensive crisis or hypertensive encephalopathy.

          7. History of stroke or transient ischemic attack within the past 6 months.

          8. Significant vascular disease (eg, aortic aneurysm requiring surgical repair or recent
             peripheral arterial thrombosis) within 6 months prior to initiation of therapy.

          9. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess within the past 6 months.

         10. Patients with symptomatic sensory or peripheral neuropathy (Grade 2 or above).

         11. Patients may not have received other agents, either investigational or marketed, that
             act by primary anti-angiogenic mechanisms.

         12. Prior malignancy (except for adequately treated basal-cell or squamous-cell skin
             cancers, in situ carcinomas, or low grade [Gleason score of 3+3 or less] localized
             prostate cancer) in the past 5 years.

         13. Patients with active concurrent infections or patients with serious underlying
             medical conditions.

         14. Patients receiving full-dose oral or parenteral/SC anticoagulation must be on a
             stable dosing schedule prior to enrollment; a coumadin dose must be stable for 1
             week. If this cannot be achieved, the patient will be ineligible for enrollment.

         15. Major surgical procedure or significant traumatic injury within 28 days prior to
             study initiation, or anticipation of need for major surgical procedure during the
             course of the study.

         16. Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to initiation of therapy.

         17. Patients with external biliary stents.

         18. Patients with proteinuria, as demonstrated by a urine protein of 2+ or greater at
             screening. If 2+ or greater proteinuria, a 24-hour urine can be obtained, and if the
             result is &lt;1 gm/24 hours, the patient is eligible.

         19. Any non-healing wound, ulcer, or bone fracture.

         20. Any clinical evidence or history of a bleeding diathesis or significant coagulopathy
             (in the absence of therapeutic anticoagulation).

         21. History of hemoptysis (≥½ teaspoon of bright red blood per episode) within 1 month
             prior to initiation of therapy.

         22. History of any other disease, physical examination finding, or clinical laboratory
             finding giving reasonable suspicion of a disease or condition that contraindicates
             use of an investigational drug or that might affect interpretation of the
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna C Bendell, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna C Bendell, M.D.</last_name>
    <email>asksarah@scresearch.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>asksarah@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodlands Medical Specialists</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSARAH</last_name>
      <email>AskSARAH@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSARAH</last_name>
      <email>AskSARAH@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Space Coast Cancer Center</name>
      <address>
        <city>Titusville</city>
        <state>Florida</state>
        <zip>32796</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lindap@spacecoastcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital East</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSARAH</last_name>
      <email>AskSARAH@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSARAH</last_name>
      <email>AskSARAH@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>71304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSARAH</last_name>
      <email>AskSARAH@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSARAH</last_name>
      <email>AskSARAH@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSARAH</last_name>
      <email>AskSARAH@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSARAH</last_name>
      <email>AskSARAH@scresearch.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>Aflibercept</keyword>
  <keyword>Surgery</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
